+86(1812)4514114 info@phcoker.com

Raw Semaglutide powder (910463-68-2)

Raw Semaglutide powder is a GLP-1 Receptor Agonist. The mechanism of action of Semaglutide powder is as a Glucagon-like ………


Status: In Mass Production
Synthesized and Customized Available
Capacity: 1277kg/month

 

Description

Raw Semaglutide powder (910463-68-2) video

 

Raw Semaglutide powder (910463-68-2) Description

Raw Semaglutide powder is a GLP-1 Receptor Agonist. The mechanism of action of Semaglutide powder is as a Glucagon-like Peptide-1 (GLP-1) Agonist. The chemical classification of Raw Semaglutide powder is Glucagon-Like Peptide 1.

Raw Semaglutide powder is a once-daily glucagon-like peptide-1 analog that differs to others by the presence of an acyl group with a steric diacid at Lys26 and a large synthetic spacer and modified by the presence of a α-aminobutyric acid in position 8 which gives stability against the dipeptidylpeptidase-4.[A31421] The stability of Semaglutide powder by the acylation permits a high-affinity albumin binding and gives it a long plasma half-life which allows the once-daily dosage. It was developed by the Danish pharmaceutical company Novo Nordisk and FDA approved on December 5, 2017.

Raw Semaglutide powder (910463-68-2) Specifications

Product Name Raw Semaglutide powder
Chemical Name Ozempic; UNII-53AXN4NNHX; NN9535; 53AXN4NNHX;
Sequence His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(PEG2-PEG2- γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
Brand Name Ozempic
Drug Class Peptide
CAS Number 910463-68-2
InChIKey DLSWIYLPEUIQAV-CCUURXOWSA-N
Molecular Formula C187H291N45O59
Molecular Weight 4113.641 g/mol
Monoisotopic Mass 4113.64
Melting Point  N/A
Freezing Point N/A
Biological Half-Life One week
Color Blue
Solubility  Soluble in aqueous solution (5% AcOH) (1mg/ml).
Storage Temperature  Stable for at least 1 year after receipt when stored at -20°C.
Application Antidiabetics, Glucagon-like Peptide-1 Agonists

 


=

COA

 photo COA 910463-68-2 Sermaglutide Phcoker_zps9heb4izz.jpg

References & product citations

Semaglutide Effects Only as Peptide? NO, Much More Than That!

 

References

  1. Semaglutide Versus Dulaglutide -Once Weekly in Patients with Type 2 Diabetes (SUSTAIN 7): a Randomised, Open-label, Phase 3b Trial, Richard E. Pratley, Vanita R. Aroda, Ildiko Lingvay, Jorg Ludemann, Camilla Andreassen, Andrea Navarria, Adie Viljoen Elsevier, 2018.
  2. Handbook of Incretin-based -Therapies in Type 2 Diabetes, edited by Stephen Gough, page 80-88.
  3. Semaglutide, Reduction in Glycated -Haemoglobin and the Risk of Diabetic Retinopathy, Tina Vilsboll, Stephen C. Bain, Lawrence A. Leiter, Ildiko Lingvay, David Matthews, Rarael Simo, Ida Caroe, Helmark, Nelun Wijayasingye, Michael Larsen, John Wiley $ Sons Limited, 2018.